

Enterovirus and parechovirus infection in children: a brief overview

S. C. M. de Crom^{1,2} · J. W. A. Rossen³ · A. M. van Furth⁴ · C. C. Obihara²

Received: 31 December 2015 / Revised: 25 March 2016 / Accepted: 18 April 2016 / Published online: 7 May 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract Enterovirus and parechovirus are a frequent cause of infection in children. This review is an overview of what is known from enterovirus and parechovirus infection in children and contains information about the epidemiology, pathogenesis, clinical presentation, diagnosis, treatment, and prognosis of enterovirus and parechovirus infection in children.

Conclusions: EV and HPeV infections are a frequent cause of infection in childhood. The clinical presentation is diverse. RT-qPCR is the best way to detect an EV or HPeV. Cerebrospinal fluid, blood and feces have the highest sensitivity for detecting an EV or HPeV. There is no treatment for EV and HPeV infections. Two vaccines against EV 71 are just licensed in China and will be available on the private market. Little is known about the prognosis of EV and HPeV infections.

What is known:

• *EV and HPeV are a frequent cause of infection in children.*

What is new:

• *This review gives a brief overview over EV and HPeV infection in children.*

Communicated by David Nadal

✉ S. C. M. de Crom
stephanie_de_crom@hotmail.com

¹ Department of Pediatrics, St. Elisabeth Hospital, Tilburg, The Netherlands

² Department of Pediatrics, Maastricht University Medical Centre, PO Box 5800, 6202 AZ Maastricht, The Netherlands

³ Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

⁴ Department of Pediatric Infectious Diseases Immunology and Rheumatology, VU Medical Centre, Amsterdam, The Netherlands

Keywords Enterovirus · Parechovirus · Overview · Children · Infection

Historical perspectives [1]

Human enteroviruses (EV) were originally classified according to their pathogenicity [2]. The first human enteroviruses (EV) discovered after poliovirus were the Coxsackie viruses. They were named according to the first geographical site of their isolation in New York [3]. A distinction was made between Coxsackie A viruses, which were shown to induce flaccid paralysis and affect skeletal and heart muscle in mouse models, and Coxsackie B viruses, which were shown to induce spastic paralysis and affect a wide range of mouse tissues, including the central nervous system, liver, exocrine pancreas, brown fat, and striated muscle [4]. The name Echovirus (enteric, cytopathogenic, human, orphan virus) was then chosen for the viruses [5]. Later, it was found that individual Echovirus serotypes are associated with a wide variety of clinical manifestations, as gastro-enteritis, meningitis and respiratory illness [6]. With the discovery of new EV types, it became increasingly difficult to classify them based on specific clinical manifestations as serotypes with only a few molecular differences had a different viral phenotype leading to highly diverse symptoms. Therefore, since 1974, new EVs with different serological properties have been numbered by their order of identification. More recently, thanks to molecular typing, the classification of EVs has been adapted and revised [7]. Moreover, two serologically distinct viruses, discovered in 1956 during a summer diarrhea outbreak in American children [8], were originally described as Echovirus 22 and 23 within the human EVs because of their clinical and morphological properties. However, they were shown to be distinct from EVs and other picornavirus groups

in several features of their genome organization, structure, and replication and were renamed and reclassified into their own genus, *Parechovirus* [9–11].

Picornaviruses

The *Picornaviridae* family is one of the largest RNA virus families and contains an array of pathogens that infect both humans and animals. Picornaviruses are small (~30 nm), non-enveloped viruses containing a single-stranded ribonucleic acid (RNA). The family is classified into 29 genera including the genus *Enterovirus* and *Parechovirus* (Fig. 1).


The genus *Enterovirus* is divided into 12 species (EVA-J and Rhinovirus A-C). EVA, B, C and D are found in human, whereas EV E and F are found in cattle, G in pigs and H in monkeys. EV-A consists of 25 types, EV-B 63 types, EV-C 23 types and EV-D of 5 types. The Genus *Parechovirus* is divided into 2 species (*Parechovirus A* and *B*). The species *Parechovirus A*

consists of 16 types, i.e., human parechovirus (HPeV)-1 to 16. *Parechovirus B* (formerly named *Ljungan virus*) consists of *Ljungan virus* types 1 to 4 which infect rodents [12–14]).

Epidemiology of EV and HPeV infections

EV and HPeV are a major cause of aseptic meningitis in children, especially in neonates and young infants [6, 15–17]. The incidence of EV and HPeV infections in the Netherlands is not exactly known, since it is not a notifiable infection. Verboon et al. described an incidence of 26 per 100.000 neonates (age ≤ 30 days) [18]. This incidence is probably higher since only children admitted to a neonatal intensive care unit were included. In Norway, 40 % of the children below the age of 12 months and 90 % of the children below the age of 2 year had an EV infection [19]. In the US, the incidence in children below the age of 90 days varies from 3.2 % in January till 50 % in August and October [20]. Clearly, EV infections form a

Fig. 1 Classification of the virus family Picornaviridae. The most important genera are depicted



CV: coxsackievirus. EV: enterovirus. SV: simian enterovirus. B: baboon enterovirus. E: echovirus. PV: poliovirus

seasonal pattern and the incidence is the highest in the summer and autumn [20, 21]. The incidence of HPeV infection has been underestimated, but data shows that HPeVs are at least as prevalent as EVs [22]. Serological data indicates that over 90 % of children have been infected with at least one HPeV type by the age of 2 years [23–25]. EV and HPeV infections are seen in all age groups but mainly in children below 1 year of age [23, 26, 27]. HPeV infections are rare in older children and adults, while EV infections are regularly seen in older children and adults [28]. Seventy percent of the EV infections reported to the WHO are children below the age of 10 year [27].

Pathogenesis

Enteroviruses are cytopathic. Much of the associated disease presumably results from tissue-specific cell destruction but some disease manifestations, for example, EV exanthemas and myocarditis are thought to result from the host immune response to the infection. Mostly, the actual mechanisms of virus-induced disease have not been well-characterized [29]. Transmission of EVs occur through the fecal-oral and transplacental routes and by respiratory droplets [30, 31]. The primary replication sites of EV and HPeV are the epithelial cells of the oropharyngeal and intestinal mucosa. Although some replication may occur in the nasopharynx with spread to upper respiratory tract lymphatics, most of the virus is swallowed and transferred to the stomach and lower gastro-intestinal tract. There, EVs presumably bind to specific receptors on enterocytes. The virus crosses the intestinal lining cells reaches the Peyer's patches in the lamina propria, where significant viral replication occurs [32]. This is followed by a viremia that may lead to a secondary site of tissue infection [29, 33]. Secondary infection of the central nervous system results in meningitis or encephalitis. Other tissue-specific infections can result in myocarditis or pleurodynia. Disseminated infection can lead to exanthemas, nonspecific myalgias, or severe multiple organ disease. After a primary EV or HPeV infection, there is still a possibility of viral shedding in the feces and respiratory system for several weeks [34–37]. Harvala et al. suggested that the arginine-glycine-aspartic acid (RGD) motif, which participates in cell entry, has a significant role in the pathogenesis of Coxsackievirus A9 infections [35]. Recently, Sin et al. did a review in understanding the pathogenesis of Coxsackievirus infections [38]. They concluded that although recent discoveries have been made regarding determinants of tropism, host proteins involved in replication in target cells, and mechanisms of Coxsackievirus B pathogenesis; many questions remain unanswered.

The majority of the pathogenicity studies on HPeV infection are related to HPeV-1 and HPeV-3 [28]. They suggest that the different clinical manifestations of the various types of HPeV may be explained by differences in their biological characteristics. It seems that HPeV3 lacks the arginine-

glycine-glutamic acid sequence motif at the carboxyl terminus of VP1 that is characteristic for other HPeVs and is thought to mediate the use of integrins as cell receptors, suggesting it may use a different receptor to enter cells with a potentially different tropism [23]. This unique receptor may explain why HPeV-3 is associated with neonatal sepsis and central nervous system infection. In order to verify whether the *in vitro* replication kinetics of HPeV-1 and HPeV-3 are related to their pathogenicity, Westerhuis et al. used real-time polymerase chain reaction (PCR) to study isolated HPeV-1 and HPeV-3 strains in cultures of gastrointestinal, respiratory and neuronal cell lines [39]. They found no relationship between the clinical symptoms and *in vitro* replication of the HPeV-1 strains, but the HPeV-3 strains replicated more rapidly in neuronal cells, suggesting a relationship with its neuropathogenicity. They also found that HPeV-1 could be efficiently neutralized by its specific antibody and intravenous immunoglobulins, whereas most HPeV-3 strains could not be neutralized, which may explain the milder clinical course of HPeV-1 infections. Triantafyllou et al. made the interesting observation that toll-like receptors (TLR) 8 and TLR 7 seem to act as host sensors for HPeV-1 [40]. TLR 8 and 7 are localized in endosomes where they sense viral genomic RNA which subsequently leads to the secretion of inflammatory and regulatory cytokines aimed at controlling the infection. Volpe et al. describe that TLR7 and TLR8 play an important role in the pathogenesis of white matter injury with HPeV-3 encephalitis [41]. HPeV3 is taken up by the brain microglia and the single-stranded RNA (ssRNA) binds to intracellular TLR8 to initiate the innate immune response. The resulting release of reactive oxygen and nitrogen species and proinflammatory cytokines would lead to pre-oligodendrocyte and axonal injury. After infecting the neurons, the ssRNA of HPeV-3 could active TLR8 in the cell body, especially in the developing axon and growth cone (where TLR 8 is most abundant). The result would be axonal retraction and neuronal apoptosis.

Clinical presentation of EV and HPeV infections

EVs are associated with a great variety of manifestations, varying from mild respiratory and gastrointestinal infections, herpangina, and hand-foot-and-mouth disease, to more severe diseases like pleurodynia, hepatitis, myopericarditis, pancreatitis, meningitis, encephalitis, paralysis, and neonatal sepsis leading to mortality [1, 17, 42–44]. EVs are the most important cause for viral meningitis, accounting for approximately 90 % of all cases for which an etiological agent was identified [32, 45, 46].

The most commonly circulating HPeV, HPeV-1, mainly causes mild gastrointestinal and respiratory disease although sometimes in young children more severe disease can be observed [33, 47–49]. Furthermore, HPeVs are the second most

important cause of viral sepsis-like illness and meningitis in infants [50–53]. The majority of these cases are caused by HPeV-3, which is the most pathogenic HPeV type [52, 54]. It is associated with paralysis, neonatal sepsis-like illness, and sudden death in infected infants [52, 55–59]. HPeVs have received very little attention from the scientific community in the past, but continuing reports of HPeV circulation all over the world are increasing awareness of the clinical significance of this virus group. The different clinical manifestation of the different types EV and HPeV may be explained by differences in their biological characteristics [28].

Since 2000, there were some outbreaks of severe EV-D68 and EV-D71 infections [60]. EV-D68 mostly give respiratory symptoms, but an unexpectedly high number of children have been hospitalized for severe respiratory disease due to EV-D68, requiring intensive care such as intubation and mechanical ventilation [61]. Enterovirus 71 is a common cause of hand, foot, and mouth disease and encephalitis but also can give central nervous system (CNS) involvement and cardiopulmonary failure [62].

Laboratory diagnosis of EV and HPeV infections

Reverse-transcriptase real-time quantitative PCR (RT-qPCR) has been shown to be more sensitive than viral culture in detecting both EV and HPeV RNA and has become the gold standard for diagnosing EV and HPeV infections [16, 63–68]. Besides being more sensitive, it is also easier and more rapid to perform than viral culture [28, 53, 69, 70]. It is also possible to do a genotyping with RT-qPCR of EV and HPeV [52, 71]. A RT-qPCR can be performed on different body fluids for example cerebrospinal fluid, nasopharyngeal, blood, urine, and feces specimens. Cerebrospinal fluid, blood, and feces have the highest sensitivity for detecting an EV or HPeV [69].

Prevention and treatment [54]

Although EV and HPeV are a frequent cause of serious infection in children, there are limited tools available to fight these viruses. Vaccines were only available against Poliovirus [54]. Advances have been made towards the development of a vaccine against EV-71. Three recent phase 3 clinical trials of inactivated monovalent EV-A71 vaccines manufactured in China were found to have high efficacy (80.4 %–97.4 %) against EV-A71 in infants and young children [72–74], and two of these vaccines were licensed in China in December 2015 and will be available on the private vaccine market in China. Although vaccine development for specific pathogens such as poliovirus and EV-71 is possible, developing vaccines against all members of the EV and HPeV genera is not feasible due to the large number of EVs and HPeVs serotypes.

To date, no antiviral drugs have been approved for the treatment of picornavirus infections and treatment is limited to supportive care [54]. The only option available for treatment is the administration of intravenous immunoglobulin (IVIG), but the success rate of this treatment modality is variable and possibly depends on the presence of specific neutralizing antibodies in the preparation [75–78]. Pleconaril is an oral viral capsid inhibitor with activity against picornaviruses. Results on the clinical outcome varied considerably from complete recovery to fatalities. In studies of EV meningitis, EV infections in immunocompromised hosts, and in a phase I study in neonates, pleconaril was generally well tolerated, with suggestion of benefit in some studies [79–81]. Abzug et al. performed a randomized controlled trial to the effect of treatment of pleconaril in neonates with EV sepsis [82]. They describe a shorter time to culture and PCR negativity and greater survival among pleconaril recipients. Further development and evaluation of pleconaril in children with EV infection is still needed.

Prognosis of EV and HPeV infections

Little is known about the prognosis and long-term effects of EV and HPeV meningitis in children. Only some studies with a small number of children with EV meningitis are reported.

Sells et al. did a controlled follow-up study in 1975 of 19 children 2.5–8 years of age who had been hospitalized with documented EV central nervous system infection (aseptic meningitis in 9, meningoencephalitis in 9 and acute cerebellar ataxia in 1 child) 17–67 months before evaluation [83]. Three children (16 %) had definite neurologic impairment, five (26 %) had possible impairment, and 11 (58 %) were free of detectable abnormalities. Children whose illness occurred during the first year of life, when compared to controls, were found to have significantly smaller mean head circumference (50.6 vs. 51.6 cm, $p < 0.033$), significantly lower mean I.Q. (97 vs 115, $p < 0.007$), and depressed language and speech skills. Children whose illness occurred after the first year of life were not different from their controls. They concluded that children with central-nervous-system enterovirus infection may have neurologic impairment when infection occurs in the first year of life.

Wilfert et al. performed a case control study of 9 children with an EV meningitis during the first 3 months of life [84]. Receptive vocabulary testing suggested that the receptive language functioning of the group with meningitis was significantly less than that of the control group. There was no significant difference in head circumference, no detectable sensorineural hearing loss, and no detected differences in intellectual functioning between the meningitis group and matched control subjects.

Verboon et al. described 6 neonates with EV meningoencephalitis in a neonatal intensive care unit [85]. Five infants presented with prolonged seizures, and one presented with systemic EV disease. Cranial ultrasonography showed increased echogenicity in the periventricular white matter, and MRI confirmed mild to severe white matter damage in all infants, which looked similar to periventricular leukomalacia. Two infants developed cerebral palsy: one was neurologically suspect at age 18 months, and three were developmentally normal.

Chang et al. described a larger cohort of 142 children after an EV 71 infection with CNS involvement [62]. 61 who had aseptic meningitis, 53 who had severe CNS involvement, and 28 who had cardiopulmonary failure after CNS involvement. Delayed neurodevelopment was found in only 1 of 20 patients (5 %) with severe CNS involvement and in 21 of 28 patients (75 %) with cardiopulmonary failure ($p < 0.001$). Children with cardiopulmonary failure after CNS involvement scored lower on intelligence tests than did children with CNS involvement alone ($p = 0.003$).

Conclusions

EV and HPeV infections are a major cause of infection in children. EV and HPeV infection have a great variety of clinical manifestations varying from mild gastrointestinal infections to more severe diseases like meningitis and sepsis leading to mortality. The gold standard for diagnosing EV and HPeV infection is RT-qPCR. No antiviral drugs have been approved for the treatment of EV or HPeV infections, and treatment is limited to supportive care. Vaccines to EV-A71 were developed and will be available on the private market in China soon.

Authors' contributions SC, JR, AF, CO initiated and designed the study. SC participated in data collection. SC, JR, AF, CO contributed to interpretation of the results. SC drafted the initial manuscript. All authors critically revised the paper and approved of the final manuscript as submitted.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

References

- Tapparel C, Siegrist F, Petty TJ, Kaiser L (2013) Picornavirus and enterovirus diversity with associated human diseases. *Infect Genet Evol*. doi: 10.1016/j.meegid.2012.10.016.
- Hyypia T, Hovi T, Knowles NJ, Stanway G (1997) Classification of enteroviruses based on molecular and biological properties. *J Gen Virol*. doi: 10.1099/0022-1317-78-1-1.
- Dalldorf G, Sickles GM (1948) An unidentified, filtrable agent isolated from the feces of children with paralysis. *Science* 108:61
- Crowell RL, Landau BJ (1997) A short history and introductory background on the coxsackieviruses of group B. *Curr Top Microbiol Immunol* 233:1
- ENTERIC cytopathogenic human orphan (ECHO) viruses(1955). *Science*;122:1187
- Grist NR, Bell EJ, Assaad F, Grist NR, Bell EJ, Assaad F (1978) Enteroviruses in human disease. *Prog Med Virol* 24:114
- Poyry T, Kinnunen L, Hyypia T, Brown B, Horsnell C, Hovi T, Stanway G (1996) Genetic and phylogenetic clustering of enteroviruses. *J Gen Virol*. doi: 10.1099/0022-1317-77-8-1699.
- Wigand R, Sabin AB (1961) Properties of ECHO types 22, 23 and 24 viruses. *Arch Gesamte Virusforsch* 11:224
- Hyypia T, Horsnell C, Maaronen M, Khan M, Kalkkinen N, Auvinen P, Kinnunen L, Stanway G (1992) A distinct picornavirus group identified by sequence analysis. *Proc Natl Acad Sci U S A* 89:8847
- Stanway G, Hyypia T (1999) Parechoviruses. *J Virol* 73:5249
- Stanway G, Kalkkinen N, Roivainen M, Ghazi F, Khan M, Smyth M, Meurman O, Hyypia T (1994) Molecular and biological characteristics of echovirus 22, a representative of a new picornavirus group. *J Virol* 68:8232
- www.picomaviridae.com
- <http://www.ictvonline.org/virusTaxonomy.asp>
- ICTV Master species list 2014 version 4. http://talk.ictvonline.org/files/ictv_documents/m/msl/5208.aspx
- Khetsuriani N, Lamonte A, Oberste MS, Pallansch M (2006) Neonatal enterovirus infections reported to the national enterovirus surveillance system in the United States, 1983–2003. *Pediatr Infect Dis J*. doi: 10.1097/01.inf.0000237798.07462.32
- Rittichier KR, Bryan PA, Bassett KE, Taggart EW, Enriquez FR, Hillyard DR, Byington CL (2005) Diagnosis and outcomes of enterovirus infections in young infants. *Pediatr Infect Dis J* 24:546
- Sawyer MH (2002) Enterovirus infections: diagnosis and treatment. *Semin Pediatr Infect Dis* 13:40
- Verboon-Maciolek MA, Krediet TG, van Loon AM, Kaan J, Galama JM, Gerards LJ, Fleer A (2002) Epidemiological survey of neonatal non-polio enterovirus infection in the Netherlands. *J Med Virol* 66:241
- Witso E, Palacios G, Cinek O, Stene LC, Grinde B, Janowitz D, Lipkin WI, Ronningen KS (2006) High prevalence of human enterovirus a infections in natural circulation of human enteroviruses. *J Clin Microbiol* 44:4095
- Byington CL, Taggart EW, Carroll KC, Hillyard DR (1999) A polymerase chain reaction-based epidemiologic investigation of the incidence of nonpolio enteroviral infections in febrile and afebrile infants 90 days and younger. *Pediatrics* 103:E27
- Lee BE, Chawla R, Langley JM, Forgie SE, Al-Hosni M, Baerg K, Husain E, Strong J, Robinson JL, Allen U, Law BJ, Dobson S, Davies HD (2006) Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of aseptic meningitis. *BMC Infect Dis* 6:68
- Benschop K, Thomas X, Serpenti C, Molenkamp R, Wolthers K (2008) High prevalence of human Parechovirus (HPeV) genotypes in the Amsterdam region and identification of specific HPeV variants by direct genotyping of stool samples. *J Clin Microbiol*. doi: 10.1128/JCM.01379-08.
- Harvala H, Wolthers KC, Simmonds P (2010) Parechoviruses in children: understanding a new infection. *Curr Opin Infect Dis* 23:224
- Joki-Korpela P, Hyypia T (1998) Diagnosis and epidemiology of echovirus 22 infections. *Clin Infect Dis* 27:129
- Tauriainen S, Martiskainen M, Oikarinen S, Lonnrot M, Viskari H, Ilonen J, Simell O, Knip M, Hyoty H (2007) Human parechovirus 1

- infections in young children—no association with type 1 diabetes. *J Med Virol*. doi: [10.1002/jmv.20831](https://doi.org/10.1002/jmv.20831).
26. Khatami A, McMullan BJ, Webber M, Stewart P, Francis S, Timmers KJ, Rodas E, Druce J, Mehta B, Sloggett NA, Cumming G, Papadakis G, Kesson AM (2015) Sepsis-like disease in infants due to human parechovirus type 3 during an outbreak in Australia. *Clin Infect Dis*. doi: [10.1093/cid/ciu784](https://doi.org/10.1093/cid/ciu784).
 27. Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA, Centers for Disease Control and Prevention (2006) Enterovirus surveillance—United States, 1970–2005. *MMWR Surveill Summ* 55(8):1–20
 28. Esposito S, Rahamat-Langendoen J, Ascolese B, Senatore L, Castellazzi L, Niesters HG (2014) Pediatric parechovirus infections. *J Clin Virol*. doi: [10.1016/j.jcv.2014.03.003](https://doi.org/10.1016/j.jcv.2014.03.003).
 29. Palacios G, Oberste MS (2005) Enteroviruses as agents of emerging infectious diseases. *J Neurovirol* 11:424
 30. Bendig JW, Franklin OM, Hebden AK, Backhouse PJ, Clewley JP, Goldman AP, Piggott N (2003) Coxsackievirus B3 sequences in the blood of a neonate with congenital myocarditis, plus serological evidence of maternal infection. *J Med Virol*. doi: [10.1002/jmv.10437](https://doi.org/10.1002/jmv.10437).
 31. Konstantinidou A, Anninos H, Spanakis N, Kotsiakis X, Syridou G, Tsakris A, Patsouris E (2007) Transplacental infection of Coxsackievirus B3 pathological findings in the fetus. *J Med Virol*. doi: [10.1002/jmv.20887](https://doi.org/10.1002/jmv.20887).
 32. Rotbart HA (2000) Viral meningitis. *Semin Neurol*. doi: [10.1055/s-2000-9427](https://doi.org/10.1055/s-2000-9427).
 33. Harvala H, Simmonds P (2009) Human parechoviruses: biology, epidemiology and clinical significance. *J Clin Virol*. doi: [10.1016/j.jcv.2009.03.009](https://doi.org/10.1016/j.jcv.2009.03.009).
 34. Long S, Pickering LK, Prober CG (2003) *Pediatric Infectious Diseases*, 2nd edn., pp 1179–1187
 35. Harvala H, Kalimo H, Stanway G, Hyypia T (2003) Pathogenesis of coxsackievirus A9 in mice: role of the viral arginine-glycine-aspartic acid motif. *J Gen Virol*. doi: [10.1099/vir.0.19246-0](https://doi.org/10.1099/vir.0.19246-0).
 36. Kapusinszky B, Minor P, Delwart E (2012) Nearly constant shedding of diverse enteric viruses by two healthy infants. *J Clin Microbiol*. doi: [10.1128/JCM.01589-12](https://doi.org/10.1128/JCM.01589-12).
 37. Wildenbeest JG, Benschop KS, Bouma-de Jongh S, Wolthers KC, Pajkrt D (2016) Prolonged Shedding of Human Parechovirus in Feces of Young Children After Symptomatic Infection. *Pediatr Infect Dis J*. doi: [10.1097/INF.0000000000001082](https://doi.org/10.1097/INF.0000000000001082).
 38. Sin J, Mangale V, Thienphrapa W, Gottlieb RA, Feuer R (2015) Recent progress in understanding coxsackievirus replication, dissemination, and pathogenesis. *Virology*. doi: [10.1016/j.virol.2015.06.006](https://doi.org/10.1016/j.virol.2015.06.006).
 39. Westerhuis BM, Koen G, Wildenbeest JG, Pajkrt D, de Jong MD, Benschop KS, Wolthers KC (2012) Specific cell tropism and neutralization of human parechovirus types 1 and 3: implications for pathogenesis and therapy development. *J Gen Virol*. doi: [10.1099/vir.0.043323-0](https://doi.org/10.1099/vir.0.043323-0).
 40. Triantafilou K, Vakakis E, Orthopoulos G, Ahmed MA, Schumann C, Lepper PM, Triantafilou M (2005) TLR8 and TLR7 are involved in the host's immune response to human parechovirus 1. *Eur J Immunol*. doi: [10.1002/eji.200526149](https://doi.org/10.1002/eji.200526149).
 41. Volpe JJ (2008) Neonatal encephalitis and white matter injury: more than just inflammation?. *Ann Neurol*. doi: [10.1002/ana.21466](https://doi.org/10.1002/ana.21466).
 42. de Crom SC, van Furth MA, Peeters MF, Rossen JW, Obihara CC (2012) Characteristics of pediatric patients with enterovirus meningitis and no cerebral fluid pleocytosis. *Eur J Pediatr*. doi: [10.1007/s00431-011-1626-z](https://doi.org/10.1007/s00431-011-1626-z).
 43. Singer JI, Maur PR, Riley JP, Smith PB (1980) Management of central nervous system infections during an epidemic of enteroviral aseptic meningitis. *J Pediatr* 96:559
 44. Wilfert CM, Lehrman SN, Katz SL (1983) Enteroviruses and meningitis. *Pediatr Infect Dis* 2:333
 45. Rantakallio P, Leskinen M, von Wendt L (1986) Incidence and prognosis of central nervous system infections in a birth cohort of 12,000 children. *Scand J Infect Dis* 18:287
 46. Vollbach S, Muller A, Drexler JF, Simon A, Drosten C, Eishubinger AM, Panning M (2015) Prevalence, type and concentration of human enterovirus and parechovirus in cerebrospinal fluid samples of pediatric patients over a 10-year period: a retrospective study. *Virol J*. doi: [10.1186/s12985-015-0427-9](https://doi.org/10.1186/s12985-015-0427-9).
 47. Berkovich S, Pangan J (1968) Recoveries of virus from premature infants during outbreaks of respiratory disease: the relation of ECHO virus type 22 to disease of the upper and lower respiratory tract in the premature infant. *Bull N Y Acad Med* 44:377
 48. Ehms A, Eriksson M (1993) Epidemiological features of type 22 echovirus infection. *Scand J Infect Dis* 25:275
 49. Wildenbeest JG, Wolthers KC, Straver B, Pajkrt D (2013) Successful IVIG treatment of human parechovirus-associated dilated cardiomyopathy in an infant. *Pediatrics*. doi: [10.1542/peds.2012-1136](https://doi.org/10.1542/peds.2012-1136).
 50. Abed Y, Boivin G (2006) Human parechovirus types 1, 2 and 3 infections in Canada. *Emerg Infect Dis* 12:969
 51. Benschop KS, Schinkel J, Minnaar RP, Pajkrt D, Spanjerberg L, Kraakman HC, Berkhout B, Zaaijer HL, Beld MG, Wolthers KC (2006) Human parechovirus infections in Dutch children and the association between serotype and disease severity. *Clin Infect Dis* 42:204
 52. Harvala H, Robertson I, Chieochansin T, McWilliam Leitch EC, Templeton K, Simmonds P (2009) Specific association of human parechovirus type 3 with sepsis and fever in young infants, as identified by direct typing of cerebrospinal fluid samples. *J Infect Dis*. doi: [10.1086/599094](https://doi.org/10.1086/599094).
 53. Wolthers KC, Benschop KS, Schinkel J, Molenkamp R, Bergevoet RM, Spijkerman IJ, Kraakman HC, Pajkrt D (2008) Human parechoviruses as an important viral cause of sepsislike illness and meningitis in young children. *Clin Infect Dis*. doi: [10.1086/589752](https://doi.org/10.1086/589752)
 54. van der Linden L, Wolthers KC, van Kuppeveld FJ (2015) Replication and Inhibitors of Enteroviruses and Parechoviruses. *Viruses*. doi: [10.3390/v7082832](https://doi.org/10.3390/v7082832).
 55. Boivin G, Abed Y, Boucher FD (2005) Human parechovirus 3 and neonatal infections. *Emerg Infect Dis*. doi: [10.3201/eid1101.040606](https://doi.org/10.3201/eid1101.040606).
 56. Sainato R, Flanagan R, Mahlen S, Fairchok M, Braun L (2011) Severe human parechovirus sepsis beyond the neonatal period. *J Clin Virol*. doi: [10.1016/j.jcv.2011.02.009](https://doi.org/10.1016/j.jcv.2011.02.009).
 57. Schuffenecker I, Javouhey E, Gillet Y, Kugener B, Billaud G, Floret D, Lina B, Morfin F (2012) Human parechovirus infections, Lyon, France, 2008–10: evidence for severe cases. *J Clin Virol*. doi: [10.1016/j.jcv.2012.04.016](https://doi.org/10.1016/j.jcv.2012.04.016).
 58. Selvarangan R, Nzabi M, Selvaraju SB, Ketter P, Carpenter C, Harrison CJ (2011) Human parechovirus 3 causing sepsis-like illness in children from midwestern United States. *Pediatr Infect Dis J*. doi: [10.1097/INF.0b013e3181fbefc8](https://doi.org/10.1097/INF.0b013e3181fbefc8).
 59. Verboon-Macielek MA, Groenendaal F, Hahn CD, Hellmann J, van Loon AM, Boivin G, de Vries LS (2008) Human parechovirus causes encephalitis with white matter injury in neonates. *Ann Neurol*. doi: [10.1002/ana.21445](https://doi.org/10.1002/ana.21445).
 60. Esposito S, Bosis S, Niesters H, Principi N (2015) Enterovirus D68 Infection. *Viruses*. doi: [10.3390/v7112925](https://doi.org/10.3390/v7112925)
 61. Messacar K, Schreiner TL, Maloney JA, Wallace A, Ludke J, Oberste MS, Nix WA, Robinson CC, Glode MP, Abzug MJ, Dominguez SR (2015) A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. *Lancet*. doi: [10.1016/S0140-6736\(14\)62457-0](https://doi.org/10.1016/S0140-6736(14)62457-0).
 62. Chang LY, Huang LM, Gau SS, Wu YY, Hsia SH, Fan TY, Lin KL, Huang YC, Lu CY, Lin TY (2007) Neurodevelopment and

- cognition in children after enterovirus 71 infection. *N Engl J Med*. doi: [10.1056/NEJMoa065954](https://doi.org/10.1056/NEJMoa065954)
63. Andreoletti L, Blassel-Damman N, Dewilde A, Vallee L, Cremer R, Hober D, Wattré P (1998) Comparison of use of cerebrospinal fluid, serum, and throat swab specimens in diagnosis of enteroviral acute neurological infection by a rapid RNA detection PCR assay. *J Clin Microbiol* 36:589
 64. Benschop K, Molenkamp R, van der Ham A, Wolthers K, Beld M (2008) Rapid detection of human parechoviruses in clinical samples by real-time PCR. *J Clin Virol* 41:69
 65. Carroll KC, Taggart B, Robison J, Byington C, Hillyard D (2000) Evaluation of the roche AMPLICOR enterovirus PCR assay in the diagnosis of enteroviral central nervous system infections. *J Clin Virol* 19:149
 66. Riding MH, Stewart J, Clements GB, Galbraith DN (1996) Enteroviral polymerase chain reaction in the investigation of aseptic meningitis. *J Med Virol* 50:204
 67. Vuorinen T, Vainionpää R, Hyypia T (2003) Five years' experience of reverse-transcriptase polymerase chain reaction in daily diagnosis of enterovirus and rhinovirus infections. *Clin Infect Dis*. doi: [10.1086/376635](https://doi.org/10.1086/376635)
 68. Yerly S, Gervaix A, Simonet V, Caflisch M, Perrin L, Wunderli W (1996) Rapid and sensitive detection of enteroviruses in specimens from patients with aseptic meningitis. *J Clin Microbiol* 34:199
 69. de Crom SC, Obihara CC, de Moor RA, Veldkamp EJ, van Furth AM, Rossen JW (2013) Prospective comparison of the detection rates of human enterovirus and parechovirus RT-qPCR and viral culture in different pediatric specimens. *J Clin Virol*. doi: [10.1016/j.jcv.2013.07.017](https://doi.org/10.1016/j.jcv.2013.07.017)
 70. Nix WA, Maher K, Johansson ES, Niklasson B, Lindberg AM, Pallansch MA, Oberste MS (2008) Detection of all known parechoviruses by real-time PCR. *J Clin Microbiol*. doi: [10.1128/JCM.00277-08](https://doi.org/10.1128/JCM.00277-08)
 71. Nix WA, Oberste MS, Pallansch MA (2006) Sensitive, seminested PCR amplification of VP1 sequences for direct identification of all enterovirus serotypes from original clinical specimens. *J Clin Microbiol* 44:2698
 72. Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, Jiang L, Dong C, Che Y, Huang T, Jiang Z, Xie Z, Wang L, Liao Y, Liang Y, Nong Y, Liu J, Zhao H, Na R, Guo L, Pu J, Yang E, Sun L, Cui P, Shi H, Wang J, Li Q (2014) An inactivated enterovirus 71 vaccine in healthy children. *N Engl J Med*. doi: [10.1056/NEJMoa1303224](https://doi.org/10.1056/NEJMoa1303224)
 73. Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, Hu Y, Ji T, Song L, Liang Q, Zhang B, Gao Q, Li J, Wang S, Hu Y, Gu S, Zhang J, Yao G, Gu J, Wang X, Zhou Y, Chen C, Zhang M, Cao M, Wang J, Wang H, Wang N (2014) Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. *N Engl J Med*. doi: [10.1056/NEJMoa1304923](https://doi.org/10.1056/NEJMoa1304923)
 74. Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, Hu YM, Wu X, Liu P, Zhu LY, Gao F, Jin H, Chen YJ, Dong YY, Liang YC, Shi NM, Ge HM, Liu L, Chen SG, Ai X, Zhang ZY, Ji YG, Luo FJ, Chen XQ, Zhang Y, Zhu LW, Liang ZL, Shen XL (2013) Efficacy, safety, and immunology of an inactivated alum-adjunct enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. doi: [10.1016/S0140-6736\(13\)61049-1](https://doi.org/10.1016/S0140-6736(13)61049-1)
 75. Abzug MJ, Keyserling HL, Lee ML, Levin MJ, Rotbart HA (1995) Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. *Clin Infect Dis* 20:1201
 76. Nagington J (1982) Echovirus 11 infection and prophylactic antiserum. *Lancet* 1:446
 77. Wildenbeest JG, van den Broek PJ, Benschop KS, Koen G, Wierenga PC, Vossen AC, Kuijpers TW, Wolthers KC (2012) Pleconaril revisited: clinical course of chronic enteroviral meningoencephalitis after treatment correlates with in vitro susceptibility. *Antivir Ther*. doi: [10.3851/IMP1936](https://doi.org/10.3851/IMP1936)
 78. Yen MH, Huang YC, Chen MC, Liu CC, Chiu NC, Lien R, Chang LY, Chiu CH, Tsao KC, Lin TY (2015) Effect of intravenous immunoglobulin for neonates with severe enteroviral infections with emphasis on the timing of administration. *J Clin Virol*. doi: [10.1016/j.jcv.2015.01.013](https://doi.org/10.1016/j.jcv.2015.01.013)
 79. Abzug MJ, Cloud G, Bradley J, Sanchez PJ, Romero J, Powell D, Lepow M, Mani C, Capparelli EV, Blount S, Lakeman F, Whitley RJ, Kimberlin DW, National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (2003) Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. *Pediatr Infect Dis J*. doi: [10.1097/01.inf.0000059765.92623.70](https://doi.org/10.1097/01.inf.0000059765.92623.70)
 80. Desmond RA, Accortt NA, Talley L, Villano SA, Soong SJ, Whitley RJ (2006) Enteroviral meningitis: natural history and outcome of pleconaril therapy. *Antimicrob Agents Chemother* 50:2409
 81. Rotbart HA, Webster AD, Pleconaril Treatment Registry Group (2001) Treatment of potentially life-threatening enterovirus infections with pleconaril. *Clin Infect Dis* 32:228
 82. Abzug MJ, Michaels MG, Wald E, Jacobs RF, Romero JR, Sanchez PJ, Wilson G, Krogstad P, Storch GA, Lawrence R, Shelton M, Palmer A, Robinson J, Dennehy P, Sood SK, Cloud G, Jester P, Acosta EP, Whitley R, Kimberlin D, National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (2016) A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis. *J Pediatric Infect Dis Soc*. doi: [10.1093/jpids/piv015](https://doi.org/10.1093/jpids/piv015)
 83. Sells CJ, Carpenter RL, Ray CG (1975) Sequelae of central-nervous-system enterovirus infections. *N Engl J Med*. doi: [10.1056/NEJM197507032930101](https://doi.org/10.1056/NEJM197507032930101)
 84. Wilfert CM, Thompson RJ Jr, Sunder TR, O'Quinn A, Zeller J, Blacharsh J (1981) Longitudinal assessment of children with enteroviral meningitis during the first three months of life. *Pediatrics* 67:811
 85. Verboon-Macielek MA, Groenendaal F, Cowan F, Govaert P, van Loon AM, de Vries LS (2006) White matter damage in neonatal enterovirus meningoencephalitis. *Neurology*. doi: [10.1212/01.wnl.0000208429.69676.23](https://doi.org/10.1212/01.wnl.0000208429.69676.23)